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Abstract Undifferentiated connective tissue disease
(UCTD) is a distinct clinical entity that may be accompa-
nied by interstitial lung disease (ILD). The natural history
of UCTD-ILD is unknown. We hypothesized that patients
with UCTD-ILD would be more likely to have improve-
ment in lung function than those with idiopathic pulmonary
ﬁbrosis (IPF) during longitudinal follow-up. We identiﬁed
subjects enrolled in the UCSF ILD cohort study with a
diagnosis of IPF or UCTD. The primary outcome com-
pared the presence or absence of a C5% increase in percent
predicted forced vital capacity (FVC) in IPF and UCTD.
Regression models were used to account for potential
confounding variables. Ninety subjects were identiﬁed; 59
subjects (30 IPF, 29 UCTD) had longitudinal pulmonary
function data for inclusion in the analysis. After accounting
for baseline pulmonary function tests, treatment, and
duration between studies, UCTD was associated with
substantial improvement in FVC (odds ratio = 8.23, 95%
conﬁdence interval, 1.27–53.2; p = 0.03) during follow-up
(median, 8 months) compared with IPF. Patients with
UCTD-ILD are more likely to have improved pulmonary
function during follow-up than those with IPF. These
ﬁndings demonstrate the clinical importance of identifying
UCTD in patients presenting with an ‘‘idiopathic’’ inter-
stitial pneumonia.
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The clinical and management implications of a diagnosis of
interstitial lung disease (ILD) superimposed on an under-
lying connective tissue disease (CTD) are unclear and may
depend on the underlying CTD. In systemic sclerosis, ILD
has surpassed renal involvement as the most common cause
of death [1]. Patients with dermatomyositis/polymyositis
(DM/PM)-associated ILD have been shown to have sig-
niﬁcantly better survival compared with patients with idi-
opathic pulmonary ﬁbrosis (IPF) [2]. However, recent
retrospective studies comparing patients with CTD-associ-
ated ILD with patients with idiopathic interstitial pneumo-
nia found that after adjusting for age and other important
clinical covariates, there were similar 2- and 5-year survival
rates for the two groups [3, 4]. In a more recent study,
patients with IPF were found to have much worse outcome
compared with subjects with CTD-associated ILD (hetero-
geneous mix of CTD) [5].
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DOI 10.1007/s00408-009-9226-7As many as 25% of patients with features of a systemic
autoimmune disease do not fulﬁll American College of
Rheumatology (ACR) classiﬁcation criteria for a deﬁned
connective tissue disease (CTD) [6–10]. These patients are
considered to have diffuse or undifferentiated connective
tissue disease (UCTD) [6–10]. The majority of these
individuals (65–94%) do not develop into a ‘‘differenti-
ated’’ CTD (such as rheumatoid arthritis, systemic lupus
erythematosus, systemic sclerosis, mixed connective tissue
disease, etc.) even after years of follow-up [6–11]. There-
fore, it has been proposed that UCTD is a distinct clinical
entity with the following criteria: signs and symptoms
suggestive of a connective-tissue disease, positive sero-
logical results, and disease duration of at least 1 year
[11–14].
When criteria for UCTD are applied to a cohort of
patients with ILD, approximately 10% have UCTD-ILD
[14]. Almost 90% of patients who would have been pre-
viously characterized as ‘‘idiopathic’’ NSIP with surgical
lung biopsies met criteria for UCTD [14]. Because the
clinical entity ‘‘idiopathic’’ NSIP has been shown to have a
better prognosis in terms of survival time than IPF [15, 16],
one might expect that patients with UCTD should have a
less progressive lung disease and better prognosis. Conse-
quently, we hypothesized that patients with UCTD-ILD
would be more likely to have an improvement in lung
function as measured by change in forced vital capacity
(FVC) or diffusing capacity of carbon monoxide (DLCO)
than patients with IPF during longitudinal follow-up.
Methods
Study Subjects and Diagnostic Criteria
We reviewed the medical records of patients consecutively
enrolled in the UCSF Interstitial Lung Disease clinic from
January 1, 2004 to June 1, 2007 (n = 90) who met the
diagnostic criteria of idiopathic pulmonary ﬁbrosis or
undifferentiated connective tissue. Patients were consid-
ered to have UCTD if their medical record identiﬁed signs/
symptoms and laboratory ﬁndings that met the criteria for
UCTD (n = 42) as previously published (Table 1)[ 14].
The control group consisted of 48 consecutive patients with
idiopathic pulmonary ﬁbrosis (IPF) diagnosed according to
consensus criteria [17]. Patients with at least one follow-up
set of pulmonary function tests (met American Thoracic
Society quality standards) comprised the study cohort
(n = 59: 29 UCTD, 30 IPF). All subjects were seen in the
ILD clinic at the University of California San Francisco.
The subjects were enrolled into a Committee on Human
Research approved protocol investigating the natural
history of ILD. Informed consent was obtained from all
subjects at the time of the initial visit. A portion of these
patients were part of a previous cross-sectional study [14].
Clinical, Radiographic, and Pathologic Characteristics
These clinical characteristics were documented at the ini-
tial visit: age, ethnicity, gender, date of ﬁrst symptom onset
(cough, dyspnea, or wheeze), symptoms of connective
tissue disease, smoking status, pulmonary function tests,
and serologic tests as previously described [14]. The
symptoms and signs of connective tissue disease were
systematically collected on all cohort members as part of a
standardized questionnaire. Changes in PFTs were deter-
mined by calculating absolute change of percent predicted
and absolute value of FVC and DLCO from the initial
value until the ﬁrst follow-up.
HRCT scans were performed on all patients during the
initial evaluation. The scans were reviewed in a blinded
fashion by chest radiologists experienced in the interpre-
tation of diffuse lung disease. The speciﬁc ﬁndings on
HRCT were documented for the index scan (ﬁrst scan
documenting presence of ILD).
Table 1 Diagnostic criteria for patients with undifferentiated con-
nective tissue disease (UCTD)
Diagnostic criteria Presence of
Symptoms associated
with connective tissue
disease
At least one of the following symptoms:
1. Raynaud’s phenomenon
2. Arthralgias/multiple joint swelling
3. Photosensitivity
4. Unintentional weight loss
5. Morning stiffness
6. Dry mouth or dry eyes (sicca features)
7. Dysphagia
8. Recurrent unexplained fever
9. Gastroesophageal reﬂux
10. Skin changes (rash)
11. Oral ulceration
12. Nonandrogenic alopecia
13. Proximal muscle weakness
Evidence of systemic
inﬂammation in the
absence of infection
At least one of the following positive:
1. Antinuclear antigen
2. Rheumatoid factor
3. Anti-SCL 70 antibody
4. SS-A or SS-B
5. Jo-1 antibody
6. Sedimentation rate ([2 times normal)
7. or CRP
Derived from references [10, 12, 13]
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123Surgical lung biopsies were obtained to conﬁrm the his-
topathologic pattern of IIP in 29 cases (IPF = 14;
UCTD = 15). All lung biopsy specimens were reviewed by
a lung pathologist with experience and advanced training in
the evaluation of diffuse lung disease and were classiﬁed
usingthehistopathologicpatternsdescribedintheAmerican
ThoracicSociety/European Respiratory Society (ATS/ERS)
International Consensus Classiﬁcation of the IIPs [17].
Statistical Analysis
Continuous data are expressed as means or medians with
observed range. Categorical data are expressed as per-
centages. The primary outcome compared the presence or
absence of a C5% increase in percent predicted forced vital
capacity (FVC) in IPF and UCTD. Secondary outcomes
included presence or absence of improvement in DLCO
(deﬁned as increase of C10% predicted) and change in
percent predicted FVC during the follow-up interval. The
former was analyzed as a dichotomous variable and the
latter as a continuous variable.
Logistic regression analysis was used to estimate the
impact of a UCTD diagnosis versus IPF diagnosis on
presence/absence of improvement in FVC and DLCO.
Linear regression analysis was used to estimate the impact
of a UCTD diagnosis versus IPF diagnosis on change in
FVC over time. Other clinical variables included in the
initial regression analyses were age, gender, smoking sta-
tus, baseline percent predicted FVC, and baseline percent
predicted DLCO, treatment, composite physiologic index
(CPI) [18] and duration between PFT studies. To include
all potentially signiﬁcant variables in the regression mod-
els, both stepwise and backward elimination model-build-
ing approaches were used after candidate variables were
identiﬁed using unadjusted analysis with a predetermined
cutoff signiﬁcance level of p = 0.10 and those with a priori
importance. Variables identiﬁed as signiﬁcant by stepwise
or backward elimination were then included in a regression
model that was ﬁtted using backward elimination.
Regression models were carefully checked for evidence of
colinearity.
All p values correspond to two-sided tests and statistical
signiﬁcance was deﬁned as p\0.05. All analyses were
performed with STATA statistical software (version 9.2).
Results
The study cohort consisted of 29 patients with UCTD-ILD
and 30 IPF control subjects who had at least two sets of
pulmonary function tests. Thirty-one patients did not have
follow-up pulmonary function tests and were not included
in the ﬁnal study cohort (UCTD = 13; IPF = 18). There
was no statistical difference in baseline pulmonary function
studies or clinical characteristics in these excluded patients
compared with the study cohort except that the excluded
subjects were older (mean age, 62 vs. 70 years; p = 0.003;
data not shown). Notably, among those without complete
follow-up data, there were two conﬁrmed deaths in the IPF
group and none in the UCTD group. The study subjects’
median duration between pulmonary functions tests was
8.3 (interquartile range, 5–13) months. The median dura-
tion since ﬁrst onset of symptoms among the UCTD group
was 3.5 years (data not shown).
Thirteen of 14 patients (93%) with the diagnosis of IPF
had the usual interstitial pneumonia pattern on lung biopsy,
whereas the other patient had a nonclassiﬁable ﬁbrosis
pattern but a HRCT scan consistent with IPF. Among the
patients with UCTD, 12 of 15 patients (80%) had a NSIP
pattern on lung biopsy, 2 had a nonclassiﬁable ﬁbrosis
pattern (13%), and 1 had a lymphocytic interstitial pneu-
monia pattern (7%).
The patients with UCTD were more likely to be women,
younger, nonsmokers, and to have received immunomod-
ulatory agents (cyclophosphamide, azathioprine, or myco-
phenolate mofetil) and/or corticosteroids (p\0.0001;
Table 2). There were no statistically signiﬁcant differences
between the two study populations in baseline pulmonary
function tests.
During follow-up, 38% of patients with UCTD-ILD
improved (C5% increase in percent predicted FVC), 34%
stabilized, and 28% declined (C5% decrease in percent
predicted FVC) in lung function. In contrast, 6% of IPF
patients improved, 47% stabilized, and 47% declined in
lung function (Fig. 1). When patients were categorized as
improved or not improved, the following baseline predic-
tors were associated with the improved outcome in unad-
justed analysis: UCTD diagnosis (vs. IPF), female gender,
lifetime nonsmoker, absence of honeycombing on HRCT,
and presence of ground glass opacities on HRCT (Table 3).
The UCTD subjects had a meanincrease of 3.08% predicted
FVC per year, whereas IPF subjects had a mean decrease of
3.13% predicted FVC per year during follow-up.
Inmultivariatelogisticregressionanalysis,afteradjusting
for treatment (corticosteroids and/or immunosuppressant),
durationbetweenPFTstudies,andbaselineFVC,UCTDwas
associated with substantial improvement in FVC compared
with IPF (odds ratio = 8.23; 95% conﬁdence interval (CI),
1.27–53.2;p = 0.03;Tables 4,5).Therelationshipbetween
underlying diagnosis and improvement in DLCO ([10%
increase in percent predicted) was in a similar direction but
waslessdramaticanddidnotreachstatisticalsigniﬁcance.In
amultivariatelinearregressionmodeladjustedfortreatment,
durationbetweenPFTstudies,andbaselineFVC,UCTDwas
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123associated with a mean 5.7% higher FVC % predicted
change (median, 8 months) compared with IPF (95% CI,
0.9–10;p = 0.022;Table 5).Althoughasimilardirectionin
the relationship was seen in mean change of percent pre-
dicted DLCO, the association was not statistically
signiﬁcant.
Discussion
In this study, we evaluated the short-term longitudinal
changes in pulmonary function in individuals with the
recently described distinct rheumatologic entity, UCTD-
ILD [14], and compared their course to that found in
patients with IPF. Our study shows that patients with
UCTD-ILD have a more favorable clinical course than do
patients with IPF (as measured by change in forced vital
capacity)—a parameter associated with increased mortality
in patients with IPF, the ILD with the most robust clinical
outcome data available [19].
Patients with idiopathic NSIP have features suggestive
of an autoimmune disease [5, 15, 20, 21]. Recently, we
showed that patients with the histopathological pattern of
NSIP, in the absence of a deﬁned classic CTD, had con-
siderable, if not complete, overlap with the clinical diag-
nosis of undifferentiated connective tissue disease [14].
This is consistent with ﬁndings showing the NSIP pattern
to be the most common histopathological pattern found in
patients with the ‘‘classic’’ CTDs, such as scleroderma,
rheumatoid arthritis, Sjo ¨gren’s disease, systemic lupus
erythematosus, and polymyositis/dermatomyositis. Impor-
tantly, patients with ‘‘classic’’ CTDs have a better prog-
nosis compared with patients with IPF [2, 5]. Our ﬁndings
show that UCTD-ILD similarly seems to have a better
prognosis than IPF, at least in the short term.
We chose an improvement of at least 5% in predicted
FVC as our threshold for physiologic improvement
because recent prospective clinical studies of ILD suggest
that such a magnitude of change in FVC is appropriate
given the typical annual change in this parameter [22, 23],
even with effective therapy [24–26]. Indeed, large multi-
center, clinical trials, recently enrolling (IPFnet, CAPAC-
ITY), were powered to detect differences of this magnitude
in longitudinal change of FVC percent predicted. Fur-
thermore, in a recent clinical trial of IPF, a change of 5%
in predicted FVC was shown to be strongly associated with
mortality [27].
Our study demonstrates that patients with UCTD-ILD
were more likely to receive immunomodulatory treatments
than were patients with IPF. This likely represents a tem-
poral trend away from the use of these agents in IPF [28–
30]. A higher number of patients with UCTD-ILD than IPF
had an improvement in functional parameters while on
Table 2 Demographic and
clinical characteristics of study
cohort
a v
2 or Fisher’s exact test where
appropriate
b Include cyclophosphamide,
azathioprine, or mycophenolate
mofetil
Characteristics UCTD patients
(n = 29)
IPF patients
(n = 30)
p Value
a
Age (years) (mean, SD) 50 (11) 65 (9) \0.0001
Male (number, %) 10 (34) 24 (80) \0.0001
Ever smoker (number, %) 9 (31) 22 (73) 0.001
Ethnic background
White (number, %) 18 (62) 24 (80) 0.13
Interval between PFTs (months) (median,
interquartile range)
8.5 (4–15) 8.7 (7–13) 0.47
Medication use (number, %)
Immunomodulators
b 23 (79%) 5 (17%) \0.0001
Corticosteroids 26 (90%) 14 (47%) \0.0001
Baseline pulmonary function tests
FVC, % predicted (mean, SD) 65 (19) 71 (19) 0.21
DLCO, % predicted (mean, SD) 46 (23) 50 (13) 0.43
TLC, % predicted (mean, SD) 68 (15) 70 (15) 0.67
Presence of obstructive defect (number, %) 1 (3) 1 (3) 0.98
Fig. 1 Outcome in change of FVC in UCTD and IPF. Improved is
C?5% in FVC, stable[-5% to\?5%, worsened\-5%
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123therapy, but our study was not powered to demonstrate the
full range of clinically signiﬁcant differences regarding
treatment. Whether the difference in outcome is secondary
to a different underlying natural disease course for UCTD-
ILD or responsiveness to therapy cannot be determined
from our study. Based on our data, we cannot recommend
any speciﬁc treatment course for these patients. However,
the signals in the data suggest the possibility of a treatment
response to immunomodulatory therapy in patients with
UCTD-ILD and should be rigorously evaluated in future
studies.
There are several limitations of this study; most are
related to its retrospective design. First, approximately one-
third of potentially eligible patients with IPF or UCTD at
the study center did not have more than one set of pul-
monary function tests available for evaluation and thus
Table 3 Factors associated
with improvement in FVC
percent predicted (C5%
improvement) in unadjusted
analysis
FVC forced vital capacity,
UCTD undifferentiated
connective tissue disease, IPF
idiopathic pulmonary ﬁbrosis
Fisher’s exact test
Predictor variables Improved
number (%)
Not improved
number (%)
Risk ratio 95% CI p Value
UCTD 11 (38) 18 (62) 5.7 1.4–23.5 0.005
IPF 2 (7) 28 (93)
Male 4 (12) 30 (88) 0.33 0.11–0.94 0.05
Female 9 (36) 16 (64)
Ever smoker 3 (10) 28 (90) 0.27 0.08–0.89 0.03
Nonsmoker 10 (36) 18 (64)
Immunomodulator use 9 (32) 19 (68) 2.5 0.86–7.2 0.12
No immunomodulator use 4 (13) 27 (87)
Prednisone use 11 (28) 29 (72) 2.6 0.64–10.6 0.19
No prednisone use 2 (11) 17 (89)
Honeycombing on HRCT 1 (4) 27 (96) 0.09 0.01–0.66 0.001
No honeycombing HRCT 12 (39) 19 (61)
Ground glass opacity on HRCT 11 (42) 15 (58) 7.0 1.7–28.8 0.001
No ground glass opacity on HRCT 2 (6) 31 (94)
Table 4 UCTD versus IPF diagnosis in improvement in FVC percent predicted (C5%) or DLCO percent predicted (C10% change) in adjusted
analysis (multiple logistic regression)
Odds ratio 95% conﬁdence interval p Value
Improvement (C5%) in FVC percent predicted
UCTD versus IPF
a 8.23 1.27–53.2 0.03
Improvement (C10%) in DLCO percent predicted
UCTD versus IPF
a 3.95 0.34–46.4 0.27
UCTD undifferentiated connective tissue disease, FVC forced vital capacity, IPF idiopathic pulmonary ﬁbrosis, DLCO diffusing capacity of
carbon monoxide
a Adjusted for treatment (corticosteroids and/or immunosuppressant), duration between PFT studies, and baseline value
Table 5 UCTD versus IPF diagnosis in change of FVC percent predicted and DLCO percent predicted in adjusted (multiple) linear regression
analysis
Difference in mean change
percent predicted during follow-up
b
95% conﬁdence interval p Value
Change in FVC percent predicted
UCTD versus IPF
a ?5.7% ?0.9 to ?10% 0.022
Change in DLCO percent predicted
UCTD versus IPF
a ?3.7% -3.0 to 10.3% 0.271
UCTD undifferentiated connective tissue disease, FVC forced vital capacity, IPF idiopathic pulmonary ﬁbrosis, DLCO diffusing capacity of
carbon monoxide
a Adjusted for treatment (corticosteroids and/or immunosuppressant), duration between PFT studies, and baseline value
b Median follow-up time was 8 months
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123could not be included in this study. We attempted to mit-
igate this limitation by assessing whether these patients
were systematically different from the patients who were
included in the study in terms of demographic factors or
baseline pulmonary function tests. There were no signiﬁ-
cant differences in baseline pulmonary function tests
(including FVC and DLCO); however, the non-study
patients were older, as described above. Second, patients
had follow-up pulmonary function tests at different time
intervals. Although the standard clinical practice was to
recommend repeat tests every 3–6 months, there were no
formal protocols in place to ensure that this occurred. We
addressed this limitation in the analysis phase by using
regression techniques. Lastly, the single-center design and
heterogeneity in treatment recommendations by the indi-
vidual providers limited our power to observe differential
effects of treatment between these populations and within
the population of UCTD-ILD.
Our ﬁndings of a demonstrably different disease course
in functional changes between IPF and UCTD-ILD is an
important ﬁrst step. These results demonstrate the impor-
tance of identifying an underlying undifferentiated con-
nective tissue disorder when patients present with incipient
interstitial lung disease. Equipped with these data, the
clinician can provide better prognostic advice for patients
with UCTD-ILD.
These results will need to be conﬁrmed in prospective
studies with more standardized and complete follow-up.
Additionally, it will be important to demonstrate whether
the differences in functional parameters seen between these
two populations are accompanied by differences in the
most meaningful of outcomes—mortality—and patient-
centered outcomes, such as change in dyspnea. In addition,
there is much to be learned about the underlying patho-
genesis of UCTD-ILD and to identify appropriate targets
for well-designed intervention trials. Lastly, it will be
important to establish whether any clinical, biologic, or
serologic features can identify which patients are most at
risk for progressive disease and lung-related death.
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